(Q42130644)

English

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.

scientific article published on 5 February 2008

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

17 October 2017

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. (English)

1 reference

Europe PubMed Central

PMC publication ID

17 October 2017

peginterferon alfa-2a

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Tawesak Tanwandee

7

object named as

Tawesak Tanwandee

1 reference

Europe PubMed Central

PMC publication ID

17 October 2017

Teerha Piratvisuth

1

object named as

Teerha Piratvisuth

1 reference

Europe PubMed Central

PMC publication ID

17 October 2017

author name string

George Lau

2

1 reference

Europe PubMed Central

PMC publication ID

17 October 2017

You-Chen Chao

3

1 reference

Europe PubMed Central

PMC publication ID

17 October 2017

Rui Jin

4

1 reference

Europe PubMed Central

PMC publication ID

17 October 2017

Anuchit Chutaputti

5

1 reference

Europe PubMed Central

PMC publication ID

17 October 2017

Q-B Zhang

6

1 reference

Europe PubMed Central

PMC publication ID

17 October 2017

Peter Button

8

1 reference

Europe PubMed Central

PMC publication ID

17 October 2017

Matei Popescu

9

1 reference

Europe PubMed Central

PMC publication ID

17 October 2017

publication date

5 February 2008

1 reference

Europe PubMed Central

PMC publication ID

17 October 2017

Hepatology international

1 reference

Europe PubMed Central

PMC publication ID

17 October 2017

2

1 reference

Europe PubMed Central

PMC publication ID

17 October 2017

1

1 reference

Europe PubMed Central

PMC publication ID

17 October 2017

102-110

1 reference

Europe PubMed Central

PMC publication ID

17 October 2017

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Preventing and treating hepatitis B infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Hepatitis B virus infection--natural history and clinical consequences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Results of lamivudine trials in Asia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Interferon-alpha for HBeAg-positive chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Review article: current management of chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Treatment of HBeAg-negative chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Management of chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Treatment of chronic hepatitis B: case selection and duration of therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Management of hepatitis B: 2000--summary of a workshop

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Chronic hepatitis B virus infection in Asian countries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Profound suppression of hepatitis B virus replication with lamivudine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Update on diagnosis, management, and prevention of hepatitis B virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Interferon-alpha2b therapy is efficacious in Asian-Americans with chronic hepatitis B infection: a prospective controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

29 May 2018

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

17 August 2018

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

17 August 2018

Determinants for sustained HBeAg response to lamivudine therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

17 August 2018

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

17 August 2018

Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

17 August 2018

Long-term clinical impact of occult hepatitis B virus infection in chronic hepatitis B patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

17 August 2018

Long-term evaluation of recombinant interferon alpha2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

17 August 2018

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

17 August 2018

Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

17 August 2018

Comparative study of three doses of interferon-alpha 2a in chronic active hepatitis B. The International Hepatitis Trial Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

17 August 2018

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2716864

3 November 2018

Long-term remission of chronic hepatitis B after alpha-interferon therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19669285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B

1 reference

https://pubmed.ncbi.nlm.nih.gov/19669285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic hepatitis B: update of recommendations

1 reference

https://pubmed.ncbi.nlm.nih.gov/19669285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://pubmed.ncbi.nlm.nih.gov/19669285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis B genotypes and the response to interferon therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19669285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://pubmed.ncbi.nlm.nih.gov/19669285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/19669285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis B

1 reference

https://pubmed.ncbi.nlm.nih.gov/19669285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic hepatitis B

1 reference

https://pubmed.ncbi.nlm.nih.gov/19669285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19669285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B

1 reference

https://pubmed.ncbi.nlm.nih.gov/19669285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12072-007-9022-5

1 reference

Europe PubMed Central

PMC publication ID

17 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

17 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42130644&oldid=2205069260"